Table 1 Twist and E-cadherin expression in relation to clinicopathological findings
| Â | Â | Twist | P | E-cadherin | P | ||
|---|---|---|---|---|---|---|---|
| Â | Total ( n = 166) | High | Low | Â | Preserved | Reduced | Â |
| Â | Â | n = 70 (40.2%) | n = 96 (57.8%) | Â | n =67 (40.4%) | n =99 (59.6%) | Â |
Age |  | 65.1 ± 9.0 | 63.7 ± 9.4 | 0.52 | 63.6 ± 9.8 | 64.8 ± 8.9 | 0.70 |
Sex | Â | Â | Â | Â | Â | Â | Â |
   Male | 149 (89.8) | 63 (90.0) | 86 (89.6) | 0.93 | 59 (88.1) | 90 (90.9) | 0.56 |
   Female | 17 (10.2) | 7 (10.0) | 10 (10.4) |  | 8 (11.9) | 9 (9.1) |  |
Tumor location | Â | Â | Â | Â | Â | Â | Â |
   Upper | 28 (16.9) | 16 (22.9) | 12 (12.5) | 0.21 | 13 (19.4) | 15 (15.2) | 0.70 |
   Middle | 76 (45.8) | 29 (41.4) | 47 (49.0) |  | 31 (46.3) | 45 (45.5) |  |
   Lower | 62 (37.4) | 25 (35.7) | 37 (38.5) |  | 23 (34.3) | 39 (39.4) |  |
Histology | Â | Â | Â | Â | Â | Â | Â |
   Well | 63 (38.0) | 31 (44.3) | 32 (33.3) | 0.26 | 24 (35.8) | 39 (39.4) | 0.13 |
   Moderate | 76 (45.8) | 27 (38.6) | 49 (51.0) |  | 36 (53.7) | 40 (40.4) |  |
   Poor | 27 (16.3) | 12 (17.1) | 15 (15.6) |  | 7 (10.5) | 20 (20.2) |  |
pT | Â | Â | Â | Â | Â | Â | Â |
   pT1 | 46 (27.7) | 10 (14.3) | 36 (37.5) | 0.0044 | 33 (49.3) | 13 (13.1) | <.0001 |
   pT2 | 25 (15.1) | 10 (14.3) | 15 (15.6) |  | 11 (16.4) | 14 (14.1) |  |
   pT3 | 67 (40.4) | 34 (48.6) | 33 (34.4) |  | 14 (20.9) | 53 (53.5) |  |
   pT4 | 28 (16.9) | 16 (22.9) | 12 (12.5) |  | 9 (13.4) | 19 (19.2) |  |
pN | Â | Â | Â | Â | Â | Â | Â |
   pN0 | 65 (39.2) | 21 (30.0) | 44 (45.8) | 0.038 | 44 (65.7) | 21 (21.2) | <.0001 |
   pN1 | 101 (60.8) | 49 (70.0) | 52 (54.2) |  | 23 (34.3) | 78 (78.8) |  |
pM | Â | Â | Â | Â | Â | Â | Â |
   pM0 | 118 (71.1) | 42 (60.0) | 76 (79.2) | 0.0073 | 58 (86.6) | 60 (60.6) | 0.0002 |
   pM1 | 48 (28.9) | 28 (40.0) | 20 (20.6) |  | 9 (13.4) | 39 (39.4) |  |
pStage | Â | Â | Â | Â | Â | Â | Â |
   I | 30 (18.1) | 7 (10.0) | 23 (24.0) | 0.0011 | 26 (38.8) | 4 (4.0) | <.0001 |
   IIA | 29 (17.5) | 10 (14.3) | 19 (19.8) |  | 15 (22.4) | 14 (14.1) |  |
   IIB | 21 (12.7) | 4 (5.7) | 17 (17.7) |  | 10 (14.9) | 11 (11.1) |  |
   III | 38 (22.9) | 21 (30.0) | 17 (17.7) |  | 7 (10.5) | 31 (31.1) |  |
   IV | 48 (28.9) | 28 (40.0) | 20 (20.8) |  | 9 (13.4) | 39 (39.4) |  |
Lymphatic invasion | Â | Â | Â | Â | Â | Â | Â |
   Positive | 107 (64.5) | 55 (78.6) | 52 (54.2) | 0.0010 | 33 (49.3) | 74 (74.8) | 0.0008 |
   Negative | 59 (35.5) | 15 (21.4) | 44 (45.8) |  | 34 (50.8) | 25 (25.3) |  |
Venous invasion | Â | Â | Â | Â | Â | Â | Â |
   Positeive | 51 (30.7) | 26 (37.1) | 25 (26.0) | 0.13 | 17 (25.4) | 34 (34.3) | 0.22 |
   Negative | 115 (69.3) | 44 (62.9) | 71 (74.0) |  | 50 (74.6) | 65 (65.7) |  |
E-cadherin expression | Â | Â | Â | Â | Â | Â | Â |
   Preserved | 67 (40.4) | 20 (28.6) | 47 (49.0) | 0.0076 |  |  |  |
   Reduced | 99 (59.6) | 50 (71.4) | 49 (51.0) |  |  |  |  |